NASDAQ:TSRO - TESARO Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$74.96Today's Range$74.94 - $74.9752-Week Range$23.41 - $75.16Volume1.19 million shsAverage Volume1.97 million shsMarket Capitalization$4.13 billionP/E RatioN/ADividend YieldN/ABeta0.38 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Receive TSRO News and Ratings via Email Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:TSRO Previous Symbol CUSIP88156910 CIK1491576 Webhttp://www.tesarobio.com/ Phone339-970-0900Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$223.33 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($9.17) Net Income$-496,120,000.00 Net Margins-295.67% Return on Equity-1,209.72% Return on Assets-83.34%Miscellaneous EmployeesN/A Outstanding Shares55,050,000Market Cap$4.13 billion Next Earnings DateN/A OptionableOptionable TESARO (NASDAQ:TSRO) Frequently Asked Questions What is TESARO's stock symbol? TESARO trades on the NASDAQ under the ticker symbol "TSRO." How were TESARO's earnings last quarter? TESARO Inc (NASDAQ:TSRO) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.66) by $0.38. The biopharmaceutical company had revenue of $57.21 million for the quarter, compared to the consensus estimate of $65.50 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. The company's revenue for the quarter was up 94.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.82) earnings per share. View TESARO's Earnings History. What price target have analysts set for TSRO? 18 equities research analysts have issued 12 month price targets for TESARO's shares. Their predictions range from $25.00 to $85.00. On average, they expect TESARO's share price to reach $66.5714 in the next twelve months. View Analyst Price Targets for TESARO. What is the consensus analysts' recommendation for TESARO? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 15 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TESARO. What are Wall Street analysts saying about TESARO stock? Here are some recent quotes from research analysts about TESARO stock: 1. Cantor Fitzgerald analysts commented, ": 12-month PT of $68 on shares of TSRO. Bloomberg reported last week that Tesaro was exploring a sale. We think that the company remains undervalued based on 1) PARP inhibitor potential in first-line ovarian cancer and 2) potential with its immuno-oncology platform (licensed from AnaptysBio, ANAB, OW, covered by Eliana Merle) that is beginning to shape up with data readouts. We also believe that it can take time for deals to emerge, so we think that this press article could be a way of garnering interest for the company beyond potentially initial interest. In the past, we think that this company had been a potential takeout interest from biopharmaceutical companies." (11/19/2018) 2. According to Zacks Investment Research, "TESARO's drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2018) Has TESARO been receiving favorable news coverage? Media stories about TSRO stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TESARO earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of TESARO's key competitors? Some companies that are related to TESARO include BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA) and Alnylam Pharmaceuticals (ALNY). What other stocks do shareholders of TESARO own? Based on aggregate information from My MarketBeat watchlists, some companies that other TESARO investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Clovis Oncology (CLVS), Micron Technology (MU), Celgene (CELG), Tesla (TSLA), Exelixis (EXEL), Gilead Sciences (GILD) and Intel (INTC). Who are TESARO's key executives? TESARO's management team includes the folowing people: Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43) How big of a company is TESARO? TESARO has a market capitalization of $0.00 and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. What is TESARO's official website? The official website for TESARO is http://www.tesarobio.com/. How can I contact TESARO? TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900. MarketBeat Community Rating for TESARO (NASDAQ TSRO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 615 (Vote Outperform)Underperform Votes: 471 (Vote Underperform)Total Votes: 1,086MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What Are Treasury Bonds? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.